Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Psychedelic Drug Legislative Reform and Legalization in the US
Joshua S. Siegel, James E. Daily, Demetrius A. Perry, et al.
JAMA Psychiatry (2022) Vol. 80, Iss. 1, pp. 77-77
Open Access | Times Cited: 95

Showing 1-25 of 95 citing articles:

Naturalistic psilocybin use is associated with persisting improvements in mental health and wellbeing: results from a prospective, longitudinal survey
Sandeep M. Nayak, Hillary Jackson, Nathan D. Sepeda, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 48
Psychedelics in Psychiatry: Oh, What A Trip!
Gregory A. Fonzo, Charles B. Nemeroff, Ned H. Kalin
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 1-5
Closed Access | Times Cited: 2
The Psychedelic Future of Post-Traumatic Stress Disorder Treatment
Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic, et al.
Current Neuropharmacology (2024) Vol. 22, Iss. 4, pp. 636-735
Open Access | Times Cited: 16
The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world
Stephanie Lake, Philippe Lucas
International Journal of Drug Policy (2024) Vol. 130, pp. 104507-104507
Closed Access | Times Cited: 11
Psychedelic-assisted psychotherapy: where is the psychotherapy research?
Jacob S. Aday, David Horton, Gisele Fernandes‐Osterhold, et al.
Psychopharmacology (2024) Vol. 241, Iss. 8, pp. 1517-1526
Closed Access | Times Cited: 10
Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps
Eyal Kurzbaum, Tomáš Páleníček, Amiel Shrchaton, et al.
Journal of Fungi (2025) Vol. 11, Iss. 2, pp. 99-99
Open Access | Times Cited: 1
Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?
Christina M. Andrews, Wayne Hall, Keith Humphreys, et al.
Addiction (2024)
Open Access | Times Cited: 8
A Transformative Trip? Experiences of Psychedelic Use
Logan Neitzke‐Spruill, Caroline Beit, Jill O. Robinson, et al.
Neuroethics (2024) Vol. 17, Iss. 2
Open Access | Times Cited: 7
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
Psilocybin for clinical indications: A scoping review
Kim Madden, Breanne Flood, Darren Young Shing, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 10, pp. 839-845
Open Access | Times Cited: 7
Pressing regulatory challenges for psychedelic medicine
Amy L. McGuire, Holly Fernandez Lynch, Lewis A. Grossman, et al.
Science (2023) Vol. 380, Iss. 6643, pp. 347-350
Closed Access | Times Cited: 14
Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey
Nicolas G. Glynos, Jacob S. Aday, Daniel J. Kruger, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 6
Psychedelic-assisted therapy for treating anxiety, depression, and existential distress in people with life-threatening diseases
Sivan Schipper, Kabir Nigam, Yasmin Schmid, et al.
Cochrane library (2024) Vol. 2024, Iss. 9
Closed Access | Times Cited: 6
Slouching towards engagement: interactions between people using psychedelics naturalistically and their healthcare providers
Kevin F. Boehnke, Kasey Cox, Cody Weston, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 13
Psilocybin history, action and reaction: A narrative clinical review
Pravesh Sharma, Quang A. Nguyen, Sadie J. Matthews, et al.
Journal of Psychopharmacology (2023) Vol. 37, Iss. 9, pp. 849-865
Closed Access | Times Cited: 13
Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report
Harman Chopra, Timothy Furnish, Monica Verduzco–Gutierrez, et al.
Clinical Case Reports (2024) Vol. 12, Iss. 6
Open Access | Times Cited: 4
State Cannabis and Psychedelic Legislation and Microdosing Interest in the US
Kevin H. Yang, Nora Satybaldiyeva, Matthew R. Allen, et al.
JAMA Health Forum (2024) Vol. 5, Iss. 6, pp. e241653-e241653
Open Access | Times Cited: 4
Brain Networks, Neurotransmitters and Psychedelics: Towards a Neurochemistry of Self-Awareness
Daniel C. Mograbi, Rafael Rodrigues, Bheatrix Bienemann, et al.
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 8, pp. 323-340
Open Access | Times Cited: 4
Clinical Effects of Psychedelic Substances Reported to United States Poison Centers: 2012 to 2022
Mark Simon, Heather Olsen, Christopher Hoyte, et al.
Annals of Emergency Medicine (2024) Vol. 84, Iss. 6, pp. 605-618
Closed Access | Times Cited: 4
Psychoactive substances for the treatment of neuropsychiatric disorders
Zifan Zhen, Xueqiang Sun, Shiying Yuan, et al.
Asian Journal of Psychiatry (2024) Vol. 101, pp. 104193-104193
Closed Access | Times Cited: 4
Refractory CRPS pain treated with psilocybin: A case report
David S. Jevotovsky, Harman Chopra, Court Wing, et al.
Clinical Case Reports (2024) Vol. 12, Iss. 9
Open Access | Times Cited: 4
Knowledge, attitudes, and concerns about psilocybin and MDMA as novel therapies among U.S. healthcare professionals
Erin Y. Wang, David S. Mathai, Natalie Gukasyan, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Psychedelic Regulation Beyond the Controlled Substances Act: A Three-Dimensional Framework for Characterizing Policy Options
Maha N. Mian, Michael T. Dinh, Allison R. Coker, et al.
American Journal of Psychiatry (2025) Vol. 182, Iss. 1, pp. 6-9
Closed Access
An initiative for living evidence synthesis in clinical psychedelic research
S. Parker Singleton, Brooke. L. Sevchik, Simon Vandekar, et al.
Nature Mental Health (2025) Vol. 3, Iss. 1, pp. 3-5
Closed Access
Psychedelics as moral bioenhancers: Protocol for a scoping review of ethical arguments for and against
S L Streicher, Christopher Register, Xiu Lim, et al.
Wellcome Open Research (2025) Vol. 10, pp. 3-3
Open Access
Page 1 - Next Page

Scroll to top